Proactive Investors - Run By Investors For Investors

Motif Bio higher as it presents data from Phase III iclaprim trial

The presentation provided a drill-down in the results from the company’s REVIVE study
petrie dish
Motif also provided details of a recent lab-based data supporting iclaprim’s activity against Gram-positive bacteria collected from patients

Motif Bio PLC (LON:MTFB) (NASDAQ:MTFB) shares rose on Tuesday as the firm delivered new data on its lead drug, iclaprim, at the European Congress of Clinical Microbiology and Infectious Diseases, in Amsterdam.

The presentation provided a drill-down into the results from the company’s REVIVE Phase III study of people with skin and skin structure infections.

READ: Motif Bio receives vote of confidence as it raises £2.7mln

Among the headlines was an analysis by lesion size, which showed the antibiotic had comparable efficacy to vancomycin, the current standard of care.

Delegates heard the bacteremia rates were comparable between the two drugs, while the pharmacokinetics of iclaprim (the way the drug moves around the body) supported the use of a fixed dosing regimen.

Finally, Motif provided details of a recent lab-based data supporting iclaprim’s activity against Gram-positive bacteria collected from patients.

“Data are being presented that show that iclaprim continues to be active against a variety of antibiotic-resistant pathogens like methicillin-resistant (MRSA), methicillin-susceptible (MSSA) Staphylococcus aureus, and other Gram-positive skin and soft structure pathogens collected during 2017 from Europe and the US,” Motif said.

In early afternoon trading in London, Motif Bio shares were 4.9% higher at 8.82p.

 -- Adds share price --

View full MTFB profile View Profile

Motif Bio PLC Timeline

Newswire
May 07 2019

Related Articles

knee physio
February 18 2019
Results from an eight-year clinical extension study showed that ChondroMimetic was able to regenerate cartilage to a structural quality almost identical to native cartilage
scientist in a lab
April 12 2019
Danish giant Novo Nordisk recently signed up to use its NDD platform, and bosses expect more collaboration deals in the coming months
porcupine
November 30 2018
It’s been a tricky period for Redx, but it has come through it with a promising pipeline, cash in the bank and AstraZeneca’s former UK boss as its new chief executive
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use